

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LUKASHEV, Matvey E.

Appl. No. 12/526,296

§ 371(c) Date: January 13, 2011

For: **Treatment for Multiple Sclerosis**  
(As Amended)

Confirmation No.: 5197

Art Unit: 1649

Examiner: Ulm, John D.

Atty. Docket: 2159.3210001/JMC/M-R/U-S

**Declaration of Katherine T. Dawson, M.D. Under 37 C.F.R. § 1.132**

US Patent and Trademark Office  
PO Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

I, the undersigned, Katherine T. Dawson, M.D. residing at 561 Canton Street, Westwood, MA 02090 declare and state as follows:

**I. My Background**

1. I am a Senior Director of Medical Research at Biogen Idec MA Inc. ("Biogen Idec"), the assignee of the currently pending application. I have seven years of experience in the clinical development of MS drug products. I was involved in the development of Tysabri<sup>®</sup> and was the medical director of the Avonex<sup>®</sup> program. Tysabri<sup>®</sup> and Avonex<sup>®</sup>, both parenteral therapies, are among the few currently-approved treatment options for MS patients. I am currently responsible for developing BG-12, a new oral MS therapy. A copy of my *curriculum vitae* accompanies this declaration as Exhibit A.

FORWARD PHARMA EXHIBIT 1018  
Biogen MA Inc. v. Forward Pharma A/S  
Contested Case 106.023

2. I have personal knowledge of the matters in this declaration – knowledge which is either first-hand, or derived from my experience in this field and from interacting with others on the BG-12 development team at Biogen Idec.

## **II. Long Felt Need for Oral Treatment of Multiple Sclerosis**

3. Multiple sclerosis ("MS") is an autoimmune disease characterized by inflammation, myelin destruction, axonal damage and neuronal loss in the central nervous system and affects about 2.5 million people worldwide.

4. Patients with MS are typically treated with injectable medications. Despite the recent approval of one oral MS therapy, a substantial challenge remains to develop efficacious yet safe oral therapies to treat MS patients. As such, there is a high, unmet, long-felt need for oral therapies that are effective in treating MS.

5. In an attempt to address this high, unmet, long-felt need, Biogen Idec has completed Phase 2 and Phase 3 clinical trials to investigate BG-12 as an oral treatment for MS. The only active ingredient of BG-12 is dimethyl fumarate ("DMF").

## **III. The 480 mg DMF Per Day Dose is Unexpectedly Efficacious**

### **A. Phase 2 Clinical Trial**

6. In 2004, Biogen Idec initiated a Phase 2 six-month placebo controlled clinical trial of BG-12 in 10 countries and enrolled 257 patients with relapsing remitting MS (RRMS). The clinical trial included an additional six-month safety extension. Overall, ninety-one percent of the patients completed the placebo-controlled part of the Phase 2 clinical trial.


- a. Men and women 18 to 55 years of age were eligible for the study if they had a diagnosis of RRMS and an Expanded Disability Status Scale ("EDSS") score (a well-known measure of the disabilities suffered by MS patients) between 0.0 and 5.0. Additionally, the patients had to have had at least 1 relapse within 12 months prior to randomization or gadolinium-enhancing (Gd+) lesions (Gd+ lesions in the brain are a well-known marker of MS) on brain MRI within six weeks of randomization.
  - b. The patients were randomly assigned to one of four treatment groups for 24 weeks:  
(a) 120 mg BG-12 once daily (120 mg/day); (b) 120 mg BG-12 three times daily (360 mg/day); (c) 240 mg BG-12 three times daily (720 mg/day); and (d) placebo.
  - c. The primary end point of the Phase 2 clinical trial was the sum of all new Gd+ lesions from four brain MRI scans obtained at Weeks 12, 16, 20, and 24. The number of Gd+ lesions is considered a surrogate end point for clinical efficacy and as such is accepted as a primary end point for a proof of concept study.
  - d. The secondary end points of the Phase 2 clinical trial included the cumulative number of new Gd+ lesions on scans from Weeks 4 and 24, the number of new or newly enlarging T2-hyperintense lesions at Week 24, and the number of new T1 hypointense lesions at week 24.
  - e. Additional end points included annualized relapse rate ("ARR") and disability progression as measured by EDSS.
7. The results of the Phase 2 clinical trial are reported in the peer-reviewed publication of Kappos, L., *et al.*, "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study,"

*Lancet* 372:1463-72 (2008) (Exhibit B); as well as in Kappos, L., *et al.*, "Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study," 16th Meeting of the European Neurological Society (presentation given on May 30, 2006) (Exhibit C); Kappos, L., *et al.*, "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study," 16th Meeting of the European Neurological Society (abstract to presentation given on May 30, 2006) (Exhibit D); and "Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting MS with BG-12 Led to Statistically Significant Reductions in MRI Measures," Biogen Idec News Release (May 30, 2006) (Exhibit E).

- a. Only the patients who were administered 720 mg/day DMF exhibited a statistically significant effect on the primary endpoint vs. placebo. Patients in this dose group showed a 69% decrease ( $P < 0.001$ ) in the mean number of new Gd+ lesions over MRI scans Weeks 12 to 24 as shown in Figure 1 below.

17. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the present patent application or any patent issued thereon.

Respectfully submitted,

  
Katherine T. Dawson

Date: Oct 13, 2011

1431835\_1.DOC

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.